Insights from the BPD-CN International Registry: Treatment Approaches and Challenges

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, with novel therapies being investigated.

In this podcast, you will hear from Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Nerses Ghahramanyan, MD, Yeolyan Hematology and Oncology Center, Yerevan, Armenia, Marco Herling, MD, University of Leipzig, Leipzig, Germany, and Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy, who discuss promising therapies emerging in the field, current challenges, and more.

The post Updates, challenges and novel agents being explored in BPDCN appeared first on VJHemOnc.